TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory, in good health or medically stable~* Able to understand and comply with planned study procedures~* Provide written informed consent~* Negative urine pregnancy test within 24 hours prior to vaccination (women of child-bearing potential)~Exclusion Criteria:~* Prior serious or severe reaction to influenza vaccine~* Known contraindication to either study vaccine~* Receipt of any other influenza vaccine within 180 days prior to enrollment~* Plan to receive another licensed influenza or other vaccine during the duration of this study~* Receipt of any significant new diagnosis, medication (licensed or investigational), or licensed vaccine within 30 days prior to enrollment in this study~* Underlying disease or therapeutic intervention that might adversely affect the immune response~* Plans to participate in any investigation involving an investigational product during this study.~* Pregnant, lactating or planning to become pregnant within 30 days of study vaccine.~* Any clinical or social circumstance that in the opinion of the investigator could interfere with compliance with study procedures or interfere with the interpretation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Flublok Quadrivalent Influenza Vaccine (Type: EXPERIMENTAL): Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
- Inactivated Influenza Vaccine (IIV4) (Type: ACTIVE_COMPARATOR): Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hyperpolarized Xenon Gas MR Imaging in NSCLC Radiotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is willing and able to give informed consent for participation in the trial~* Male or Female, aged 18 years or above~* Histologically verified NSCLC~* Patients with any stage NSCLC where radical radiotherapy (with either conventionally fractionated treatment or with stereotactic body radiotherapy (SABR)) or chemoradiotherapy (concurrent or sequential schedule) is considered appropriate~* WHO performance status 0-2~* Able (in the Investigators opinion) and willing to comply with all study requirements~Exclusion Criteria:~* Inability to give written informed consent~* Female participant who is pregnant, lactating or planning pregnancy during the course of the trial~* Previous radiotherapy to the chest~* The presence of another condition where the disease itself or treatment may interfere with the study endpoints~* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule~* Inability to lie flat for imaging~* Contraindications to MRI examination including indwelling pacemaker, non-MRI compatible metallic implant, severe claustrophobia, intra-ocular foreign body~* Contraindications for gadolinium enhanced lung MRI scan - known hypersensitivity/allergy to the injection of MultiHance (contains gadobenate dimeglumine and small quantities of benzyl alcohol) that is given as part of this scanning or an adverse reaction to an injection given during previous MRI scanning, severe renal impairment~* Contraindications for ventilation/perfusion nuclear medicine scanning - known hypersensitivity to albumin or preference to avoid blood donation product~* Epilepsy requiring on-going medical treatment, or a seizure within the past year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 129 Xenon MR Imaging (Type: EXPERIMENTAL): Xenon gas is inhaled immediately before acquisition of an MR image to enable the lung structure to be seen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have failed or are intolerant to anti TNFs~* hsCRP greater or equal to 5.0 mg/L~* Ulcerations demonstrated by colonoscopy as defined by SES CD assessment performed within 8 weeks of study entry (screening) and able to retrospectively complete the SES-CD or colonoscopy performed during screening~Exclusion Criteria:~* Pregnant or breastfeeding women~* Crohn's Disease with active fistulae or abscess~* History of diverticulitis or symptomatic diverticulosis~* Abnormality in hematology or chemistry profiles at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo- SC injection (Type: PLACEBO_COMPARATOR): None
- Drug Dose level 1 - SC injection (Type: EXPERIMENTAL): None
- Drug Dose level 2 - SC injection (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects completing 12 weeks treatment in Study M12-921 who would benefit from long-term treatment from ABT-SLV187. Alternatively, subjects who (i) participated in the Phase 2 Study M12-925 (ii) would, in the opinion of the Investigator, benefit from ABT-SLV187 treatment in the Study M12-923, (iii) did not discontinue the M12-925 Study due to safety reason, and (iv) meet all entry requirements. Lastly, subjects who completed another ABT-SLV187 study (e.g., Study M12-927) in South Korea.~2. The subject must be able to understand the nature of the study and must provide written informed consent prior to the conduct of any study procedures (including any changes occurring in the subject's current therapeutic regimen).~3. The subject must be willing to continue on treatment.~Exclusion Criteria:~1. Subject is enrolled in another clinical trial.~2. Psychiatric, neurological or behavioral disorders that may interfere with the ability of subjects to give informed consent, or interfere with the conduct of the study.~3. Medical, laboratory, or surgical issues deemed by the Investigator to be clinically significant and in the opinion of the PI, would be a contraindication to continued levodopa therapy.~4. Uncooperative attitude or reasonable likelihood for non-compliance with the protocol.~5. Subject has current significant suicidal ideation as evidenced by answering yes to questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale completed at the Week 12 Visit of Study M12-921 or at the Baseline Visit of the current study for M12-925 or M12-927 study subjects.~6. Consideration by the Investigator, for any reason, that the subject is an unsuitable candidate to continue to receive ABT-SLV187.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- ABT-SLV187 (Type: EXPERIMENTAL): up to 6 years

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin Deficiencies and Suppletion in Morbid Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Vitamin B12 deficiency: \<200 pmol/l~* Vitamin B12 deficiency 6-12 months after surgery~* All patients underwent a Roux-en-Y gastric bypass~Exclusion Criteria:~1. Creatin \>150micromol/L~2. Liver enzymes \>2 times upper limit~3. Other bariatric operations~4. Intercurrent diseases~5. Gastro-intestinal diseases~6. Psychiatric disease~7. Medicines which influences bone density~8. Pregnancy

- Gender: MALE
- Minimum Age: 18 Months
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- hydroxocobalamin injection (Type: ACTIVE_COMPARATOR): 25 patients receive the standard treatment of a vitamin B12 deficiency: hydroxocobalamin injection
- FitForMe vitamin B12 tablets (Type: ACTIVE_COMPARATOR): 25 patients receive a daily dose vitamine B12 tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb (BMS) Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Genotype 3 HCV~* HCV RNA ≥10000 IU (International Unit)/mL~* Compensated Liver Cirrhosis~* BMI 18-40 kg/m2~* Previously treated for HCV or never treated for HCV~Exclusion Criteria:~* Infection with HCV other than Genotype 3. Mixed infection of any genotype~* Evidence of decompensated liver disease~* Previous exposure to NS5A inhibitors~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV) (Type: EXPERIMENTAL): Oral dosing of DCV 60 mg tablet once daily + SOF 400 mg tablet once daily + RBV 1000-1200 mg tablet per day (weight based) for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of General Anesthetics on Upper Airway Collapsibility in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) class I~* Age between 18 and 45~* BMI 18-28 kg/m\^2~Exclusion Criteria:~* Concurrent significant medical illness (heart disease including untreated hypertension, Clinically significant kidney disease, liver disease, or lung disease, History of myasthenia gravis or other muscle and nerve disease)~* Anxiety disorder requiring treatment~* Concurrent medications known to affect anesthesia, upper airway muscles or respiratory function (e.g., gabaergic anxiolytics, antipsychotics)~* Individuals with a history of allergy or adverse reaction to lidocaine, propofol, or sevoflurane~* For women: pregnancy~* Suggestion of obstructive sleep apnea (OSA) or any other sleep disorder (e.g. witnessed apneas, gasping or choking during sleep, unexplained excessive daytime sleepiness)~* History of drug or alcohol abuse~* Acute intermittent porphyria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Propofol (Type: ACTIVE_COMPARATOR): The healthy subject will be anesthetized with Propofol. Respiratory measurements will be taken while the subject is anesthetized to calculate the airway closing pressure. After recovery from anesthesia, airway diameter and duty cycle will also be measured. In addition to breathing air mixture, subject will be given carbon dioxide to achieve end tidal CO2 levels of 4 mm and 8 mm above baseline. All respiratory measurements will be repeated at each level above baseline. Assessment of swallow patterns during anesthesia and wakefulness, as well as under differential CO2 levels will be assessed offline after recovery from anesthesia.
- Sevoflurane (Type: ACTIVE_COMPARATOR): The healthy subject will be anesthetized with Sevoflurane. Respiratory measurements will be taken while the subject is anesthetized to calculate the airway closing pressure. After recovery from anesthesia, airway diameter and duty cycle will also be measured. In addition to breathing air mixture, subject will be given carbon dioxide to achieve end tidal CO2 levels of 4 mm and 8 mm above baseline. All respiratory measurements will be repeated at each level above baseline. Assessment of swallow patterns during anesthesia and wakefulness, as well as under differential CO2 levels will be assessed offline after recovery from anesthesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV-1 positive by licensed diagnostic test~2. Aged 16 years or older (or minimum age as determined by local regulations or as legal requirements dictate)~3. Have received first antiretroviral regimen consisting of an NNRTI plus 2N(t)RTIs for at least 24 weeks~4. No change in antiretroviral therapy within 12 weeks prior to screening~5. Failed first-line NNRTI + 2N(t)RTI combination therapy according to virological criteria defined by two consecutive (at least 7 days apart) HIV RNA results of greater then 500 copies/mL~6. No prior or current exposure to HIV protease inhibitors and/or HIV integrase inhibitors~7. Able to provide written informed consent~Exclusion Criteria:~1. The following laboratory variables:~   * absolute neutrophil count (ANC) \< 500 cells/microlitres~  * hemoglobin \< 7.0 g/decilitres~  * platelet count \< 50,000 cells/microlitres~  * ALT great than 5 x ULN~2. Pregnant or nursing mothers~3. Participants with active viral hepatitis B infection defined by the presence in serum of hepatitis B surface antigen~4. Use of immunomodulators within 30 days prior to screening~5. Use of any prohibited medications (rifampicin, midazolam, triazolam, cisapride, pimozide, amiodarone, dihydroergotamine, ergotamine, ergonovine, methylergonovine, astemizole, terfenadine, vardenafil, and St. John's wort)~6. Intercurrent illness requiring hospitalization~7. Active opportunistic disease not under adequate control in the opinion of the site Principal Investigator~8. Participants with current alcohol or illicit substance abuse that in the opinion of the site Principal Investigator might adversely affect participation in the study~9. Participants deemed by the site Principal Investigator unlikely to be able to remain in follow-up for the protocol-defined period

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ritonavir-boosted lopinavir and 2N(t)RTI (Type: ACTIVE_COMPARATOR): This is the current standard of care for second line therapy following failure of standard first-line NNRTI+2N(t)RTIs according to WHO guidelines.
- Ritonavir-boosted lopinavir and raltegravir (Type: EXPERIMENTAL): This is an experimental arm which is likely to be fully active in the presence of N(t)RTI mutations and which preliminary evidence suggests should be potent and durable.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Part 1: healthy volunteers~* Part 2:~* study will consist of patients presenting to the UCSF interstitial lung disease (ILD) outpatient clinic with imaging indicative of lung fibrosis but of uncertain classification, and who are willing to take EGCG for a minimum of 2 weeks prior to surgery.~Exclusion Criteria:~* co-morbidities affect hepatic function, such as HCV infection, cirrhosis, or~* using drugs with significant hepatic toxicities

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- EGCG PK in healthy volunteers 450 mg (Type: OTHER): Healthy volunteers: 450 mg Epigallocatechin-3-gallate (EGCG) capsules administered once daily by mouth
- EGCG PK in healthy volunteers 600 mg (Type: OTHER): Healthy volunteers: 600 mg Epigallocatechin-3-gallate (EGCG) capsules administered once daily by mouth
- EGCG PK in healthy volunteers 750 mg (Type: OTHER): Healthy volunteers: 750 mg Epigallocatechin-3-gallate (EGCG) capsules administered once daily by mouth
- No treatment control in ILD patients (Type: NO_INTERVENTION): Patients: not treated with EGCG
- EGCG treatment in ILD patients (Type: EXPERIMENTAL): Patients: 600 mg EGCG capsules once daily by mouth for two weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug Interaction Study Between Dorzagliatin and Sitagliptin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects diagnosed with T2DM within at least 3 months prior to screening~2. Male and/or female subjects between the ages of 30 and 65 years, inclusive;~3. Body Mass Index (BMI) of 19 to 38 kg/m2, inclusive;~4. Fasting C-peptide test result \>0.3 nmol/L (\>0.90 ng/mL);~5. HbA1c ≥7% and ≤10.5%;~Exclusion Criteria:~1. Fasting blood glucose at screening or Day -1 ≤110 or ≥270 mg/dL;~2. Type 1 diabetes mellitus;~3. Reported incidence of severe or serious hypoglycemia within 3 months prior to screening;~4. Known contraindications to sitagliptin;~5. Clinically significant gastrointestinal disorder;~6. History or symptoms of clinically significant cardiovascular disease within one year prior to screening;~7. History of more than three urinary tract infections and/or more than three genital fungal infections in the last 12 months;~8. Reported history of clinically significant central nervous system disease;~9. Reported history of liver disease;~10. Reported history of clinically significant renal disease;~11. Estimated glomerular filtration rate (eGFR) ≤60 mL/min/1.73m2;~12. Acute or chronic metabolic acidosis, including diabetic ketoacidosis;~13. Known or suspected malignancy;~14. Any reported hypersensitivity or intolerance to sitagliptin;~15. Antidiabetic treatment with insulin, sulfonylureas, thiazolidinediones or GLP-1 agonist within 3 months prior to screening;~16. Systolic blood pressure \<90 or \>160 mmHg or diastolic blood pressure \<60 or \>100 mmHg at screening;~17. A hospital admission or major surgery within 90 days prior to screening;~18. Uncontrolled hypertriglyceridemia \>500 mg/dL;~19. Positive blood screen for HIV, hHBsAg, or hepatitis C antibody;~20. Positive pregnancy test result;~21. Female is breast-feeding or planning to become pregnant;~22. Treated with any investigational drugs within 6 weeks prior to screening;~23. Reported history of prescription drug abuse;~24. Reported history of alcohol abuse;~25. Reported history of donation or or acute loss of blood during the 90 days prior to screening;

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sequential arm ABC (Type: EXPERIMENTAL): A: Sitagliptin 100 mg QD in the morning on Days 1-5; B: Sitagliptin 100 mg QD in the morning and dorzagliatin 75 mg BID (morning and evening) on Days 6-10, with only the morning dose on Day 10; C: Dorzagliatin 75 mg BID (morning and evening) on Days 11-15, with only the morning dose on Day 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete